SPS is a rare neurological disorder (1–2 cases per million) with a suspected autoimmune basis. Symptoms include rigidity, pain, and spasms triggered by sensory or emotional stimuli. IVIg is the primary treatment, with SCIg as an alternative. Home infusion providers support access, payor approvals, and clinical oversight, yet limited data exist on SPS management in non-hospital settings.

Seventy-three SPS patients received home infusion Ig therapy 94% IVIg and 6% SCIg. The cohort was 83.6% female, with median age 58.  Median IVIg dosing was 1.3 g/kg/ every 4 weeks, SCIg 0.99g/kg/month (0.25g/kg weekly) over 6 injection sites, with 1271 dispenses filled (1210 IVIg/61 SCIg). Common symptoms throughout treatment included stiffness (82%), muscle weakness (79%), fatigue (77%), poor balance (65%), unsteady gait (64%), and muscle spasms (40%). Falls occurred in 3% of assessments and median pain score was 3 on a 1-10 scale.  ADRs were mostly mild or moderate, including headache, fatigue, fever, hypertension, anemia, nausea, and Infusion Site Reactions (ISRs)  of swelling, itching, rash, and redness. Serious ADRs were rare (headache and systemic hypersensitivity reactions) and no critical ADRs were reported.